Go Pro
→ When I found Rolls-Royce under $2, most people thought I was crazy (From Monument Traders Alliance) (Ad)tc pixel
NASDAQ:HELP

Cybin Q1 2025 Earnings Report

Cybin logo
$7.04 +0.53 (+8.14%)
Closing price 04:00 PM Eastern
Extended Trading
$7.09 +0.05 (+0.74%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Q1 2025
Date
8/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?
July 15 at 7:34 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cybin-d-b-helus-pharma-092213353.html
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318875/0/en/helus-pharma-reports-recent-business-highlights-and-fiscal-year-2026-financial-results.html
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 years of trading experience, one chart detail stands out above all others as the primary signal before entering any trade. The Ultimate Day Trading Cheatsheet distills that edge into 7 pages, including 23 Golden Rules and a specific trade setup with a reported 94.2% win rate. It's available at no cost.tc pixel
July 16 at 1:00 AM  |  The TradingPub (Ad)
Cybin: A Speculative Bet On Their Pivotal Depression Readout
June 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918259-cybin-a-speculative-bet-on-their-pivotal-depression-readout
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?
June 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cybin-help-28-9-phase-220929014.html
Helus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug Pipeline
June 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helus-pharma-raises-us50-million-to-advance-late-stage-mental-health-drug-pipeline?utm_source=marketbeat.com&utm_medium=referral
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. Cybin’s work spans preclinical research through clinical trials, with an emphasis on optimizing pharmacology, dosing and delivery to improve safety, tolerability and the patient experience. Its R&D approach combines chemistry, formulation science and clinical development to advance candidate therapies toward regulatory review.

Cybin’s therapeutic efforts target a range of mental health indications that commonly include mood and anxiety disorders and substance-use disorders. The company pursues both internal development programs and collaborative relationships with academic and industry partners to support clinical development, regulatory strategy and potential commercialization pathways.

As a publicly traded biotechnology company, Cybin’s operations encompass research and development activities across multiple jurisdictions, with clinical programs conducted in regions where regulatory frameworks permit investigational studies of psychedelic-assisted treatments. The company positions itself to expand therapeutic options for patients and to contribute to the evolving scientific and clinical understanding of psychedelic-derived medicines.

View Cybin Profile
Earnings Tools